Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
OCUL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.06 - $11.78
Previous CloseN/A
Volume219.73K
Average Volume (3M)1.88M
Market Cap
$1.20B
Enterprise Value$1.10B
Total Cash (Recent Filing)-$23.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 12, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding159,022,250
10 Day Avg. Volume2,024,978
30 Day Avg. Volume1,884,703
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.74
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.95
Enterprise Value/Ebitda-6.25
Forecast
1Y Price Target
$17.70Price Target Upside146.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityOCUL ended 2024 with $392M in cash, which management expects to be sufficient runway into 2028, beyond anticipated readouts in both SOL-1 and SOL-R.
Market PotentialThe global branded anti-VEGF market is projected to grow significantly, and the potential 6- to 12-month dosing intervals with Axpaxli confer blockbuster potential.
Research And DevelopmentAxpaxli stands out among development candidates due to longer duration and a unique phase 3 program.
Bears Say
Clinical Trial DelaysThe first pivotal data for Axpaxli is now pushed back slightly to 1Q26 from 4Q25.
Financial PerformanceThe net loss for the fourth quarter of 2024 was higher than estimated, with a net loss of $48.4 million.
---
Ownership Overview
3.32% Insiders
9.83% Mutual Funds
0.41% Other Institutional Investors
75.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCUL FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
Ocular Therapeutix lowest stock price was $4.06 and its highest was $11.78 in the past 12 months.
What is Ocular Therapeutix’s market cap?
Ocular Therapeutix’s market cap is $1.20B.
When is Ocular Therapeutix’s upcoming earnings report date?
Ocular Therapeutix’s upcoming earnings report date is May 12, 2025 which is in 25 days.
How were Ocular Therapeutix’s earnings last quarter?
Ocular Therapeutix released its earnings results on Mar 03, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.254 by -$0.036.
Is Ocular Therapeutix overvalued?
According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
Does Ocular Therapeutix pay dividends?
Ocular Therapeutix does not currently pay dividends.
What is Ocular Therapeutix’s EPS estimate?
Ocular Therapeutix’s EPS estimate is -0.29.
How many shares outstanding does Ocular Therapeutix have?
Ocular Therapeutix has 159,022,250 shares outstanding.
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Ocular Therapeutix reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.254. Following the earnings report the stock price went down -17.087%.
Which hedge fund is a major shareholder of Ocular Therapeutix?
Currently, no hedge funds are holding shares in OCUL
---
Ocular Therapeutix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.70 (146.86% Upside)
$17.70 (146.86% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 83%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $289.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.46%
12-Months-Change
Fundamentals
Return on Equity
-95.21%
Trailing 12-Months
Asset Growth
81.68%
Trailing 12-Months
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. (OCUL) is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies for diseases and conditions of the eye. The company's primary emphasis is on creating sustained-release therapies to enhance patient care and treatment outcomes. Ocular Therapeutix's leading product, DEXTENZA, is an FDA-approved corticosteroid insert used to treat ocular inflammation and pain following ophthalmic surgery. The company is also engaged in developing a robust pipeline of product candidates targeting various eye conditions, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and other ophthalmic diseases.
---
OCUL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress with FDA approvals and strong trial retention. Financial stability and expansion opportunities in additional indications were also emphasized. However, there were delays in timeline for topline data and a reduction in trial size, indicating some operational adjustments.Read More>---
OCUL Stock 12 Month Forecast
Average Price Target
$17.70
▲(146.86% Upside)
Technical Analysis
Opko Health
―
Pacira Pharmaceuticals
―
BioLife Solutions
―
Viridian Therapeutics
―
89bio
―
Best Analysts Covering OCUL
1 Year
1 Year Success Rate
11/23 ratings generated profit
1 Year Average Return
+25.54%
reiterated a buy rating last month
Copying Yi Chen's trades and holding each position for 1 Year would result in 47.83% of your transactions generating a profit, with an average return of +25.54% per trade.
---